History of allergic reactions attributed to compounds of similar chemical or biologic composition to tremelimumab and MEDI or previous toxicity attributed to MEDI or other PD- or PD-L directed therapy that led to drug discontinuation
History of allergic reaction attributed to compounds of similar chemical or biologic composition to the MEK inhibitor, trametinib
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel and/or both platinum-based chemotherapy agents are excluded; patient must be able to receive at least one of the two proposed chemotherapy regimens
Patients must NOT have a history of allergic reactions attributed to compounds of similar chemical or biochemical composition to cisplatin, carboplatin, etoposide, temozolomide or capecitabine
Patients who have any history of allergic reaction(s) attributed to compounds of similar composition to temozolomide, pazopanib, their metabolites, or any component of their formulation are NOT eligible for participation
Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib are not eligible; AND/OR patients who have had prior exposure to compounds of similar chemical or biologic composition to palbociclib are not eligible hypersensitivity to any component of palbociclib are not eligible for participation
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ribociclib, T-DM (Cohort A)) and/or trastuzumab (Cohorts B and C) and/or fulvestrant (Cohort C)
History of allergic reactions/hypersensitivity attributed to compounds of similar chemical or biologic composition to tamoxifen, anastrozole, or fulvestrant or any of their ingredients
History of allergic reactions or hypersensitivity to compounds of similar chemical or biologic composition to anastrozole or letrozole
History of allergic reactions attributed to compounds of similar chemical or biologic composition to navitoclax, dabrafenib, or trametinib, or excipients or to dimethyl sulfoxide (DMSO)
Known history of allergic reactions attributed to compounds of similar chemical or biologic composition to fenretinide, such as -cis-retinoic acid, retinol, or all-trans-retinoic acid
Subjects with a history of hypersensitivity to compounds of similar biologic composition to atezolizumab or any constituent of the product
Subjects with a history of hypersensitivity to compounds of similar biologic composition to atezolizumab or any constituent of the product
EXPANDED ACCESS COHORT: History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib or binimetinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab or previous toxicity attributed to pembrolizumab or other PD- directed therapy that led to permanent drug discontinuation
Patents with history of hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to platinum based chemotherapy
Known hypersensitivity to MK- (pembrolizumab) or history of allergic reactions to compounds of similar chemical or biologic composition to anti-PD or PD-L antibodies or entinostat
History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents (cyclophosphamide, busulfan, pentostatin, sirolimus, MMF, granulocyte-colony stimulating factor [G-CSF]) used in the study
Known severe hypersensitivity to selumetinib or any excipient of selumetinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib
Known hypersensitivity or allergic reactions attributed to any compounds of similar chemical or biologic composition to the study medication, such as recombinant IL- or other monoclonal antibodies
History of allergic reactions attributed to compounds of similar chemical or biologic composition to rucaparib, mirvetuximab soravtansine or monoclonal antibodies
History of significant allergic reactions attributed to compounds of similar composition to SD- or BMS-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study vaccine components and any of the chemotherapy drugs (docetaxel, carboplatin, trastuzumab, pertuzumab)
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to anti-LAG-, anti-CD, and anti-PD are ineligible; the investigator brochures can be referenced for more information
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab unless felt to be in the best interests of the patient in the opinion of the investigator
Patient must not have a history of allergic reactions like anaphylaxis attributed to compounds of similar chemical or biologic composition to meclizine such as antihistamine drugs.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to fostamatinib or paclitaxel; patients who are able to tolerate paclitaxel on a desensitization protocol will be allowed
Known severe hypersensitivity to selumetinib or olaparib, their comparators, or combination medications or any excipient of these medicinal products, or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib or olaparib, or their comparator
History of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel including to other drugs formulated in cremophor(R) EL (polyoxyethylated castor oil)
Known hypersensitivity to poziotinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to poziotinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Y-DOTA-tyr-octreotide, Octreoscan, Ga-octreotide, or I-MIBG
Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab are not eligible; known hypersensitivity to any excipients of pembrolizumab
Hypersensitivity to BV or history of allergic reaction attributed to compounds of similar chemical or biologic composition of BV
History of allergic reactions attributed to compounds of similar composition to SD- or ibrutinib
Patients with a history of allergic reactions attributed to or intolerance to compounds of similar chemical or biologic composition to either CB- or capecitabine; if capecitabine has been received previously, must have tolerated at least an equivalent dose to the dose to be administered at their assigned dose level
Known severe hypersensitivity to selumetinib or any excipient of selumetinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib
History of allergic reaction to compounds of similar chemical or biologic composition to cytarabine
History of allergic reaction attributed to compound(s) of similar chemical or biologic composition as ARQ , carboplatin, paclitaxel, or anastrozole
History of allergic reactions attributed to Flagyl (metronidazole), which has a chemical structure similar to EF
History of allergic reactions to compounds of similar composition to either CDX- or poly-ICLC
History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine, docetaxel, vorinostat, or granulocyte colony-stimulating factor (G-CSF)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to anakinra or other agents used in study; known hypersensitivity to Chinese hamster ovary (CHO)-cell derived biologics or any components of anakinra
No history of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin, lomustine, vincristine (vincristine sulfate) or cyclophosphamide
History of allergic reactions attributed to compounds of similar chemical or biologic composition to tremelimumab and durvalumab or previous toxicity attributed to durvalumab or other PD- or PD-L directed therapy that led to drug discontinuation
History of severe allergic reactions or hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to STA- (eg. Polyethylene glycol [PEG]  and Polysorbate )
Patients with known hypersensitivity to nintedanib or -azacitidine or who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to nintedanib or -azacitidine are not eligible
A history of allergic reactions or significant toxicity attributed to compounds of similar chemical or biologic composition to anti-CD mAbs, anti-PD- mAbs, or TLR agonists.
History of allergic reaction attributed to compounds of similar or biologic composition to inotuzumab ozogamicin or other agents in the study
History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to either paclitaxel or ricolinostat; patients who require administration of paclitaxel through a desensitization procedure are not eligible for this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib (difficulty breathing, lip swelling, itching or rash)
Patients who have exhibited allergic reactions to compounds structurally similar to APTO- HCI
History of allergic reactions attributed to compounds of similar chemical or biologic composition to CDX- or CDX- or poly-ICLC
History of allergic reactions attributed to compounds of similar chemical or biologic composition to G-CSF/filgrastim (Escherichia [E] coli producing cell line), plerixafor or busulfan
History of allergic reactions attributed to compounds of similar chemical or biologic composition to G-CSF/filgrastim (E. coli producing cell line) and plerixafor
History of allergic reactions attributed to compounds of similar chemical or biologic composition to HDACI, TLR-agonist, or patients with known history of pre-existing auto-immune disease
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN, including but not limited to established allergic reaction to benzodiazepines, or romidepsin; agents that alter gastric pH may change MLN absorption are not permitted; proton pump inhibitors need to be stopped  days prior to the first dose of MLN; histamine- (H) receptor antagonists are not permitted from the day prior (day -) through to the end of MLN dosing; antacid preparations are not permitted for  hours before or  hours after administration of MLN
Patients will be excluded if there is any history of allergic reaction(s) attributed to compounds of similar composition to temsirolimus, sorafenib, their metabolites, or any component of their formulation (including excipients and polysorbate ); this includes hypersensitivity to macrolide antibiotics due to potential for cross-reactivity with temsirolimus
History of allergic reactions attributed to compounds of similar chemical or biologic composition (i.e. ethanol) to XL or vemurafenib (i.e., ethanol)
Subjects with a history of allergic reactions attributed to compounds of similar composition to dolastatin or auristatin. Compounds of similar composition include Auristatin PHE as an anti-fungal agent, Auristatin PE (TZT-, Soblidotin, NSC-) as an anti-tumor agent and Symplostatin  as an anti-tumor agent.
SUB-PROTOCOL AIM A: History of allergic reactions attributed to compounds of similar chemical or biologic composition including macrolide (e.g. azithromycin, clarithromycin, dirithromycin, and erythromycin) and ketolide antibiotics
No history of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib, lenalidomide or rituximab or hypersensitivity to murine proteins or to any component of rituximab
History of allergic reactions attributable to compounds of similar chemical or biologic composition to ibrutinib or any component of pneumococcal, influenza and DTaP vaccines
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab; prior hypersensitivity reactions to anti-CD therapy or anti-CD therapy is not an exclusion criterion
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Lu-DOTA-JR as assessed from medical records
Subjects with a history of hypersensitivity to compounds of similar biologic composition to tremelimumab or any constituent of the product
Subjects with a history of hypersensitivity to compounds of similar biologic composition to durvalumab or any constituent of the product
Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK- are not eligible; known hypersensitivity to any excipients of MK-
Known allergy to any of the treatment components including a history of allergic reactions attributed to compounds of chemical or biological composition similar to olaratumab.
Patient has a history of allergic reactions to compounds of similar chemical or biological composition to buparlisib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin or omega- fatty acids
History of allergic reactions attributed to compounds of similar chemical or biologic composition to LDE  or everolimus in the study or other rapamycin analogs (e.g. sirolimus, temsirolimus)
History of allergic reactions or idiosyncrasy attributed to progestins or compounds of similar chemical structure to sodium cridanimod or lidocaine;
Patients with known grade  or greater allergic reactions attributed to compounds of similar chemical or biologic composition to mifepristone, carboplatin, or gemcitabine are ineligible for study enrollment
History of allergic reactions to compounds of similar chemical or biological composition to T DM or ONT-, except for a history of Grade  or Grade  Infusion Related Reaction to trastuzumab which has been successfully managed.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to trametinib monotherapy or trametinib in combination with GSK
History of allergic reaction attributed to compounds of similar chemical or biologic composition to eribulin mesylate, trastuzumab or pertuzumab, which cannot be managed by premedication
History of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel, trastuzumab, pertuzumab; patients with minor (grade  or ) allergic reactions to these agents, controlled with standard supportive measures, are eligible
History of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel or tryptophan containing substances. This would include L-tryptophan or -hydroxy-tryptophan supplements. Also patients with a history of severe hypersensitivity reactions to docetaxel or to other drugs formulated with polysorbate  are excluded.
Patients must not have any of the following conditions:\r\n* Recent major surgery, hormonal therapy (other than replacement) or chemotherapy, within  weeks prior to entering the study or those who have not recovered from the adverse events of treatment\r\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the chemotherapy on this trial
History of allergic reactions attributed to compounds of similar chemical or biologic composition of BKM, BYL, capecitabine (including fluorouracil), trastuzumab or lapatinib
History of allergic reactions attributed to compounds of similar chemical or biological composition to lapatinib or trastuzumab; however, patients with a history of infusion reaction to trastuzumab which was controlled with premedication on subsequent infusions without a recurring infusion reaction are eligible
History of allergic reactions attributed to compounds of similar composition to SD- or ipilimumab (anti-cytotoxic T-lymphocyte-associated protein  [CTLA] antibodies)
ERLOTINIB HYDROCHLORIDE ARM: History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib (erlotinib hydrochloride)
AKT INHIBITOR MK ARM: History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK- (Akt inhibitor MK)
LAPATINIB DITOSYLATE ARM: History of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib
SUNITINIB MALATE ARM: History of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib
Patients with a history of allergic reactions attributed to compounds of similar composition to dolastatin or auristatin; compounds of similar composition include auristatin PHE as an anti-fungal agent, auristatin PE (TZT-, Soblidotin, NSC-) as an anti-tumor agent and symplostatin  as an anti-tumor agent
Patients with a history of allergic reactions attributed to compounds of similar composition to dolastatin or auristatin (e.g. Auristatin PHE, Auristatin PE, and symplostatin)
Patients with history of allergic reactions attributed to compounds of similar composition to sirolimus, cyclophosphamide, or topotecan are not eligible
Known severe hypersensitivity to selumetinib or any excipient of selumetinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to donepezil; hypersensitivity to donepezil
History of allergic reaction attributed to compounds of similar chemical or biologic composition to paclitaxel, which cannot be managed by premedication
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK- (pembrolizumab) and interferon-gamma; patients who are hypersensitive to Escherichia (E). coli are also excluded
Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to sildenafil or phosphodiesterase- (PDE) inhibitors such as vardenafil (Levitra) and tadalafil (Cialis) are not eligible.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to amide local anesthetics, acetaminophen or dexamethasone
History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin, paclitaxel not responsive to traditional desensitization procedures
Known sensitivity to or history of allergic reactions attributed to compounds of similar chemical or biologic composition entinostat, nivolumab, or ipilimumab; history of severe hypersensitivity reaction to any monoclonal antibody
History of allergic reactions attributed to compounds of similar chemical or biologic composition to INO- and INO-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Gardasil or Gardasil 
History of allergic reactions or hypersensitivity attributed to denosumab or any components of denosumab or compounds of similar chemical or biologic composition to denosumab, such as other RANKL inhibitors
History of allergic reactions attributed to compounds of similar chemical composition to Polyphenon E (or green tea), or intravenous contrast that is required for CT scan
History of allergic reactions attributed to compounds of similar chemical composition to metformin or prior use of metformin within the last year
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Polyphenon E, tea, or any of the inactive ingredients present in the active or placebo drug products, including gelatin capsules
History of allergic reactions attributed to compounds of similar chemical or biologic composition of GARDASIL  (recombinant human papillomavirus nonavalent vaccine), including yeast allergy
History of allergic reactions attributed to compounds of similar chemical or biological composition to aspirin, NSAIDs, cyclooxygenase- (COX) inhibitors
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabazitaxel or other drugs formulated with polysorbate ; or abiraterone acetate
History of allergic reactions or hypersensitivity to compounds similar to trastuzumab and/or letrozole
History of allergic reactions attributed to compounds of similar chemical or biologic composition to DHA or corn/soy oil in placebo agent
Patient must NOT have a history of allergic reaction attributable to compounds of similar chemical or biologic composition to F-FES
Patient must NOT have a history of allergic reaction attributable to compounds of similar chemical or biologic composition to F-fluorothymidine
Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals of similar chemical or biologic composition to FLT or FDG are NOT eligible
Patients with a history of allergic reaction attributable to compounds of similar chemical or biologic composition to FFNP
Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals of similar chemical or biologic composition to FES are NOT eligible.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to copper Cu  anti-CEA monoclonal antibody MA (Cu-MA)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to indocyanine green, including those patients with a history of iodide or seafood allergy
History of allergic reactions attributed to compounds of similar chemical or biologic composition to indocyanine green, including those patients with a history of iodide or seafood allergy
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ALA; patients should refrain from use of other potential phototoxic substances (e.g. tetracyclines, sulfonamides, fluoroquinolones, hypericin extracts) for  h
History of allergic reactions to compounds of similar chemical composition to ALA
History of allergic reaction to compounds of similar composition to ferumoxytol (e.g. IV iron)
History of allergic reactions/hypersensitivity attributed to compounds of similar chemical or biologic composition to CE/BZA; (I.e. same class of drug as CE/BZA)